Carbetocin (Duratocin): Research, Benefits & Safety

Quick facts

Class: Long-acting oxytocin analog
Brand names: Duratocin, Pabal
Used for: Prevention of postpartum hemorrhage
Notable: Heat-stable formulation (WHO-relevant)
US status: Not FDA-approved; approved in many countries

Key takeaways

Carbetocin is a long-acting synthetic analog of oxytocin used to prevent postpartum hemorrhage.
A single dose provides sustained uterine contraction, often avoiding the continuous infusion oxytocin can require.
A heat-stable formulation is valued where cold-chain refrigeration is unreliable.
It is approved in many countries but is not FDA-approved in the United States.
It is a professional-use obstetric medication, not available for self-administration.

Overview

Carbetocin is a synthetic, long-acting analog of oxytocin, the natural hormone involved in uterine contraction. It was developed primarily to help prevent postpartum hemorrhage, which is excessive bleeding after childbirth and a leading cause of maternal death worldwide. Under brand names such as Duratocin and Pabal, it is used in obstetric care in many countries.

Its main advantage over oxytocin is duration. A single dose produces a more sustained uterine response, which can simplify management compared with the continuous infusion sometimes required for oxytocin. This has made carbetocin a practical option in the active management of the third stage of labor, particularly after cesarean delivery in several approved settings.

A heat-stable formulation of carbetocin has drawn significant attention from global health organizations. Because it does not require refrigeration, it offers a potential advantage in regions where reliable cold-chain storage is difficult, where the burden of postpartum hemorrhage is often highest.

How it works

Carbetocin works by binding to oxytocin receptors found in the smooth muscle of the uterus. Activating these receptors triggers strong, rhythmic uterine contractions. After delivery, sustained contraction of the uterus compresses blood vessels at the placental site, which is the body's primary mechanism for limiting blood loss.

Structurally, carbetocin is modified so that it resists the enzymatic breakdown that rapidly clears natural oxytocin. This gives it a longer duration of action from a single administration, producing a prolonged uterine response rather than the short-lived effect of oxytocin.

The practical consequence is that carbetocin can achieve sustained uterine tone without a continuous intravenous infusion in many situations. This pharmacological difference, rather than a fundamentally different target, is what distinguishes carbetocin from its parent hormone and underlies its role in preventing postpartum bleeding.

Research & evidence

Carbetocin has been studied as a uterotonic for preventing postpartum hemorrhage, with particular interest in how it compares to oxytocin, the long-standing standard. A major focus of global research was the heat-stable formulation, which was evaluated in a large World Health Organization-supported program, often referred to as the CHAMPION trial, comparing it against oxytocin in preventing blood loss after vaginal birth.

That research aimed to determine whether heat-stable carbetocin could be considered non-inferior to oxytocin, which would make it a valuable option in settings without reliable refrigeration. Interpreting such studies requires care, because non-inferiority means comparable rather than superior performance.

The broader evidence base examines carbetocin's effectiveness across different delivery scenarios and patient groups. As with any obstetric intervention, conclusions depend on the specific outcomes measured and the populations studied, and clinical guidelines continue to weigh where carbetocin fits relative to other uterotonics.

Safety & legal status

Carbetocin is intended for use only by healthcare professionals in supervised obstetric settings, and this article does not provide dosing information. Reported side effects are generally similar to those of oxytocin and can include nausea, abdominal pain, headache, flushing, and changes in blood pressure or heart rate. As an agent that strongly affects the uterus and cardiovascular system, it is used under clinical monitoring.

Its regulatory status is notable. Carbetocin is approved in many countries for preventing postpartum hemorrhage, but it has not been approved by the U.S. Food and Drug Administration. As a result, availability and approved indications differ substantially depending on the country.

This patchwork status means that clinical guidance and access vary internationally. Patients and clinicians should rely on local regulatory approvals and national guidelines, since what is standard practice in one country may be unavailable or unapproved in another.

Frequently asked questions

How is carbetocin different from oxytocin?

Carbetocin is a modified version of oxytocin designed to last longer in the body. This allows a single dose to produce sustained uterine contraction rather than the short-lived effect of oxytocin.

Why does heat stability matter?

A heat-stable formulation does not require refrigeration. This is important in regions where reliable cold-chain storage is difficult, which are often the same places where postpartum hemorrhage is most common.

Is carbetocin available in the United States?

It has not been approved by the FDA, so it is not generally available in the U.S. for this purpose, even though it is approved in many other countries.

Is carbetocin used to induce labor?

Its established role is in preventing bleeding after delivery by promoting uterine contraction, not as a general labor-induction agent. Approved indications vary by country.

Can a patient receive carbetocin on their own?

No. It is administered by healthcare professionals in supervised obstetric settings with appropriate monitoring.

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

Related guides: PT-141 · Melanotan II · Kisspeptin · All Sexual Health peptides →

Carbetocin